Remove tag oral-therapeutic
article thumbnail

PharmaShots Weekly Snapshots (June 05 – 09, 2023)

PharmaShots

Quell Therapeutics Signed an Exclusive Option and License Agreement with AstraZeneca to Develop, Manufacture and Commercialize Engineered Treg Cell Therapies Date: June 09, 2023 | Tags: Quell Therapeutics, AstraZeneca, Engineered Treg Cell Therapies, Type 1 Diabetes, Inflammatory Bowel Disease, Biotech, Treg cell engineering modules Astellas and the (..)

FDA 40
article thumbnail

PharmaShots Weekly Snapshots (February 20 - 24, 2023)

PharmaShots

Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive Positive Solid Tumors Date: Feb 23, 2023 | Tags: Keymed, Lepu Biopharma, AstraZeneca, CMG901, Claudin 18.2-Positive

FDA 40
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Axsome bounces back as FDA clears depression drug

pharmaphorum

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. Auvelity is the first drug Axsome has taken through to regulatory approval, but could be the first of a string of new products for the company, according to Tabuteau.

FDA 96
article thumbnail

Almirall and IRB Barcelona team up to tackle skin disease

pharmaphorum

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high unmet medical needs. However, states the company, many of these potentially therapeutically relevant proteins are “not amenable to conventional small-molecule inhibitors, as they lack defined ligand-binding pockets”.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. Oral therapy data presented at ASH. CellCentric, a U.K-based

article thumbnail

What states use Ozempic the most?

The Checkup by Singlecare

The #ozempic tag on TikTok has amassed over 1 billion views to date. Xenical or Alli (orlistat): Orlistat is another form of weight loss drug taken orally. Ozempic became one of the most talked about drugs in 2023. Elon Musk posted his endorsement of Ozempic on X. Jimmy Kimmel joked about it in his monologue at the 2023 Oscars.

Insurance 105
article thumbnail

Hydrocodone acetaminophen alternatives: What can I take instead of hydrocodone acetaminophen?

The Checkup by Singlecare

These alternative formulations from an oral tablet might be necessary for certain patients who are unable to take a medication like Lortab that is only available by the oral route. Belbuca is a good alternative to opioid treatment that needs to be taken around the clock, but it may come with a hefty price tag.

Dosage 52